Aristea Therapeutics was spun out of AstraZeneca to develop medicines for rare, immunologic disorders. Its lead program in development is an experimental therapy for a rare skin condition that causes repeated outbreaks of painful pustules on the hands and feet and is being looked at for other neutrophil-mediated diseases. We spoke to James Mackay, president […]

Ampio Pharmaceuticals, Inc. announced the positive data of their Phase 3 clinical trial, AP-013, which analyzed the efficacy of aspartyl-alanyl-diketopiperazine (AmpionTM) on patients experiencing severe osteoarthritis of the knee (OAK), which currently affects more than 200 million people worldwide. Ampion, an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and […]

Robert Hollingsworth, Ph.D., a former Pfizer executive who oversaw the development of cancer vaccines and immunotherapeutics, has taken on the role of the chief scientific officer at Shoreline Biosciences. Hollingsworth will be responsible for driving the development of Shoreline’s next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs). The company’s drug candidates are being developed with Shoreline’s iPSC-derived natural […]